Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Xia Dai; Zu-chun Luo; Lu Zhai; Wen-piao Zhao; Feng Huang

doi:10.1007/s13300-018-0436-y

Loading next page...

References (40)

R. Voelker (2016)
"Artificial Pancreas" Is Approved.
JAMA, 316 19
J. Sterne, M. Egger, G. Smith (2001)
Investigating and dealing with publication and other biases in meta-analysis
BMJ : British Medical Journal, 323
Rachel Gildersleeve, S. Riggs, D. Cherñavvsky, M. Breton, M. DeBoer (2017)
Improving the Safety and Functionality of an Artificial Pancreas System for Use in Younger Children: Input from Parents and Physicians.
Diabetes technology & therapeutics, 19 11
Arturo Garcia, Andrew Balo, B. Buckingham, I. Hirsch, T. Peyser (2017)
Application of Glycemic Variability Percentage: Implications for Continuous Glucose Monitor Utilization and Analysis of Artificial Pancreas Data.
Diabetes technology & therapeutics, 19 12
A. Liberati, D. Altman, J. Tetzlaff, C. Mulrow, P. Gøtzsche, J. Ioannidis, M. Clarke, P. Devereaux, J. Kleijnen, D. Moher (2009)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
The BMJ, 339
JA Sterne, M Egger, GD Smith (2001)
Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis
BMJ, 323
H. Blauw, A. Bon, R. Koops, J. deVries (2016)
Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home
Diabetes, Obesity & Metabolism, 18
H. Zayed (2016)
Genetic Epidemiology of Type 1 Diabetes in the 22 Arab Countries
Current Diabetes Reports, 16
E. Renard, A. Farret, J. Kropff, D. Bruttomesso, Mirko Messori, J. Place, Roberto Visentin, Roberta Calore, C. Toffanin, F. Palma, G. Lanzola, P. Magni, F. Boscari, S. Galasso, A. Avogaro, Patrick Keith-Hynes, B. Kovatchev, Simone Favero, C. Cobelli, L. Magni, J. DeVries (2016)
Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home
Diabetes Care, 39
(El-Khatib FH, Balliro C, Hillard MA, et al. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2016.)
El-Khatib FH, Balliro C, Hillard MA, et al. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2016.
El-Khatib FH, Balliro C, Hillard MA, et al. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2016., El-Khatib FH, Balliro C, Hillard MA, et al. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2016.
Kathryn Hurren, Jessica O’Neill (2016)
Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes
Expert Opinion on Drug Metabolism & Toxicology, 12
A. Weisman, Johnny-Wei Bai, Marina Cardinez, C. Kramer, B. Perkins (2017)
Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials.
The lancet. Diabetes & endocrinology, 5 7
Amin Sharifi, M. Bock, Dilshani Jayawardene, M. Loh, Jodie Horsburgh, Carolyn Berthold, N. Paramalingam, L. Bach, P. Colman, E. Davis, B. Grosman, C. Hendrieckx, A. Jenkins, K. Kumareswaran, N. Kurtz, A. Kyoong, R. MacIsaac, J. Speight, S. Trawley, G. Ward, Anirban Roy, T. Jones, D. O’Neal (2016)
Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study.
Diabetes technology & therapeutics, 18 12
B. Kovatchev, P. Cheng, S. Anderson, J. Pinsker, F. Boscari, B. Buckingham, F. Doyle, K. Hood, Sue Brown, M. Breton, D. Cherñavvsky, W. Bevier, P. Bradley, D. Bruttomesso, Simone Favero, Roberta Calore, C. Cobelli, A. Avogaro, T. Ly, Satya Shanmugham, E. Dassau, C. Kollman, J. Lum, R. Beck (2017)
Feasibility of Long-Term Closed-Loop Control: A Multicenter 6-Month Trial of 24/7 Automated Insulin Delivery.
Diabetes technology & therapeutics, 19 1
(2017)
systematicreview and meta-analysis of outpatient randomised controlled trials
(Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(7):501–12)
Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(7):501–12
Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(7):501–12, Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(7):501–12
(2006)
Cochrane Handbook for Systematic Reviews of Interventions Edited by Julian P. T. Higgins &
M. Breton, A. Farret, D. Bruttomesso, S. Anderson, L. Magni, S. Patek, C. Man, J. Place, Susan Demartini, Simone Favero, C. Toffanin, Colleen Hughes-Karvetski, E. Dassau, H. Zisser, F. Doyle, G. Nicolao, A. Avogaro, C. Cobelli, E. Renard, B. Kovatchev (2012)
Fully Integrated Artificial Pancreas in Type 1 Diabetes
Diabetes, 61
A. Liberati, D. Altman, J. Tetzlaff, C. Mulrow, P. Gøtzsche, J. Ioannidis, M. Clarke, P. Devereaux, J. Kleijnen, D. Moher (2009)
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
PLoS Medicine, 6
P. McEwan, H. Bennett, Jonathan Fellows, J. Priaulx, K. Bergenheim (2016)
The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus
PLoS ONE, 11
(Garcia A, Balo AK, Buckingham BA, Hirsch IB, Peyser TA. Application of glycemic variability percentage: implications for continuous glucose monitor utilization and analysis of artificial pancreas data. Diabetes Technol Ther. 2017;19(12):699–706.)
Garcia A, Balo AK, Buckingham BA, Hirsch IB, Peyser TA. Application of glycemic variability percentage: implications for continuous glucose monitor utilization and analysis of artificial pancreas data. Diabetes Technol Ther. 2017;19(12):699–706.
Garcia A, Balo AK, Buckingham BA, Hirsch IB, Peyser TA. Application of glycemic variability percentage: implications for continuous glucose monitor utilization and analysis of artificial pancreas data. Diabetes Technol Ther. 2017;19(12):699–706., Garcia A, Balo AK, Buckingham BA, Hirsch IB, Peyser TA. Application of glycemic variability percentage: implications for continuous glucose monitor utilization and analysis of artificial pancreas data. Diabetes Technol Ther. 2017;19(12):699–706.
S. Favero, J. Place, J. Kropff, Mirko Messori, Patrick Keith-Hynes, Roberto Visentin, Marco Monaro, S. Galasso, F. Boscari, C. Toffanin, F. Palma, G. Lanzola, Stefania Scarpellini, A. Farret, B. Kovatchev, Angelo Avogaro, Daniela Bruttomesso, L. Magni, J. DeVries, Claudio Cobelli, Eric Renard (2015)
Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes
Diabetes, 17
(Weinzimer SA, Steil GM, Swan KL, et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31(5):934–9)
Weinzimer SA, Steil GM, Swan KL, et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31(5):934–9
Weinzimer SA, Steil GM, Swan KL, et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31(5):934–9, Weinzimer SA, Steil GM, Swan KL, et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31(5):934–9
W. Clarke, S. Anderson, M. Breton, S. Patek, Laurissa Kashmer, B. Kovatchev (2009)
Closed-Loop Artificial Pancreas Using Subcutaneous Glucose Sensing and Insulin Delivery and a Model Predictive Control Algorithm: The Virginia Experience
Journal of Diabetes Science and Technology, 3
(2012)
Fully Integrated Arti fi cial Pancreas in Type 1 Diabetes Modular Closed-Loop Glucose Control Maintains Near Normoglycemia
J. Kropff, Simone Favero, J. Place, C. Toffanin, Roberto Visentin, Marco Monaro, Mirko Messori, F. Palma, G. Lanzola, A. Farret, F. Boscari, S. Galasso, P. Magni, A. Avogaro, Patrick Keith-Hynes, B. Kovatchev, D. Bruttomesso, C. Cobelli, J. DeVries, E. Renard, L. Magni (2015)
2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
The lancet. Diabetes & endocrinology, 3 12
J. Higgins, D. Altman (2008)
Assessing Risk of Bias in Included Studies
J. Higgins, D. Altman (2008)
Chapter 8: Assessing risk of bias in included studies
(Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley; 2008. p. 187–241.)
Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley; 2008. p. 187–241.
Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley; 2008. p. 187–241., Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley; 2008. p. 187–241.
A. Ramírez-Rincón, J. Hincapié-García, C. Arango, N. Aristizabal, Estefany Castillo, G. Hincapié, Eliana Zapata, D. Cuesta, Maria Delgado, V. Abad, José-Luis Torres, A. Palacio, J. Botero (2016)
Clinical Outcomes After 1 Year of Augmented Insulin Pump Therapy in Patients with Diabetes in a Specialized Diabetes Center in Medellín, Colombia.
Diabetes technology & therapeutics, 18 11
B. Kovatchev, E. Renard, C. Cobelli, H. Zisser, Patrick Keith-Hynes, S. Anderson, Sue Brown, D. Cherñavvsky, M. Breton, Lloyd Mize, A. Farret, J. Place, D. Bruttomesso, Simone Favero, F. Boscari, S. Galasso, A. Avogaro, L. Magni, F. Palma, C. Toffanin, Mirko Messori, E. Dassau, F. Doyle (2014)
Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas
Diabetes Care, 37
S. Russell, M. Hillard, C. Balliro, Kendra Magyar, R. Selagamsetty, M. Sinha, Kerry Grennan, Debbie Mondesir, L. Ekhlaspour, Hui Zheng, E. Damiano, F. El-Khatib (2016)
Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
The lancet. Diabetes & endocrinology, 4 3
H. Thabit, Alexandra Lubina-Solomon, M. Stadler, L. Leelarathna, E. Walkinshaw, A. Pernet, Janet Allen, A. Iqbal, P. Choudhary, K. Kumareswaran, M. Nodale, C. Nisbet, M. Wilinska, K. Barnard, D. Dunger, S. Heller, S. Amiel, M. Evans, R. Hovorka (2014)
Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.
The lancet. Diabetes & endocrinology, 2 9
S. Russell, F. El-Khatib, M. Sinha, Kendra Magyar, Katherine Mckeon, Laura Goergen, C. Balliro, M. Hillard, D. Nathan, E. Damiano (2014)
Outpatient glycemic control with a bionic pancreas in type 1 diabetes.
The New England journal of medicine, 371 4
(Gildersleeve R, Riggs SL, Cherñavvsky DR, Breton MD, DeBoer MD. Improving the safety and functionality of an artificial pancreas system for use in younger children: input from parents and physicians. Diabetes Technol Ther. 2017;19(11):660–74)
Gildersleeve R, Riggs SL, Cherñavvsky DR, Breton MD, DeBoer MD. Improving the safety and functionality of an artificial pancreas system for use in younger children: input from parents and physicians. Diabetes Technol Ther. 2017;19(11):660–74
Gildersleeve R, Riggs SL, Cherñavvsky DR, Breton MD, DeBoer MD. Improving the safety and functionality of an artificial pancreas system for use in younger children: input from parents and physicians. Diabetes Technol Ther. 2017;19(11):660–74, Gildersleeve R, Riggs SL, Cherñavvsky DR, Breton MD, DeBoer MD. Improving the safety and functionality of an artificial pancreas system for use in younger children: input from parents and physicians. Diabetes Technol Ther. 2017;19(11):660–74
J. Leahy (2008)
Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas
Yearbook of Endocrinology, 2008
(Sharifi A, De Bock MI, Jayawardene D, et al. Glycemia, treatment satisfaction, cognition, and sleep quality in adults and adolescents with type 1 diabetes when using a closed-loop system overnight versus sensor-augmented pump with low-glucose suspend function: a randomized crossover study. Diabetes Technol Ther. 2016;18(12):772–83.)
Sharifi A, De Bock MI, Jayawardene D, et al. Glycemia, treatment satisfaction, cognition, and sleep quality in adults and adolescents with type 1 diabetes when using a closed-loop system overnight versus sensor-augmented pump with low-glucose suspend function: a randomized crossover study. Diabetes Technol Ther. 2016;18(12):772–83.
Sharifi A, De Bock MI, Jayawardene D, et al. Glycemia, treatment satisfaction, cognition, and sleep quality in adults and adolescents with type 1 diabetes when using a closed-loop system overnight versus sensor-augmented pump with low-glucose suspend function: a randomized crossover study. Diabetes Technol Ther. 2016;18(12):772–83., Sharifi A, De Bock MI, Jayawardene D, et al. Glycemia, treatment satisfaction, cognition, and sleep quality in adults and adolescents with type 1 diabetes when using a closed-loop system overnight versus sensor-augmented pump with low-glucose suspend function: a randomized crossover study. Diabetes Technol Ther. 2016;18(12):772–83.
F. El-Khatib, C. Balliro, M. Hillard, Kendra Magyar, L. Ekhlaspour, M. Sinha, Debbie Mondesir, Aryan Esmaeili, Celia Hartigan, M. Thompson, S. Malkani, J. Lock, D. Harlan, Paula Clinton, E. Frank, Darrell Wilson, D. DeSalvo, Lisa Norlander, T. Ly, B. Buckingham, Jamie Diner, M. Dezube, L. Young, A. Goley, M. Kirkman, J. Buse, Hui Zheng, R. Selagamsetty, E. Damiano, S. Russell (2017)
Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial
The Lancet, 389
R. Hovorka, K. Kumareswaran, Julie Harris, Janet Allen, D. Elleri, D. Xing, C. Kollman, M. Nodale, H. Murphy, D. Dunger, S. Amiel, S. Heller, M. Wilinska, M. Evans (2011)
Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies
The BMJ, 342
(Clarke WL, Anderson S, Breton M, et al. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience. J Diabetes Sci Technol. 20091;3(5):1031–8.)
Clarke WL, Anderson S, Breton M, et al. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience. J Diabetes Sci Technol. 20091;3(5):1031–8.
Clarke WL, Anderson S, Breton M, et al. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience. J Diabetes Sci Technol. 20091;3(5):1031–8., Clarke WL, Anderson S, Breton M, et al. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience. J Diabetes Sci Technol. 20091;3(5):1031–8.

Publisher: Springer Journals
Copyright: Copyright © 2018 by The Author(s)
Subject: Medicine & Public Health; Internal Medicine; Diabetes; Cardiology; Endocrinology
ISSN: 1869-6953
eISSN: 1869-6961
DOI: 10.1007/s13300-018-0436-y
Publisher site: See Article on Publisher Site

Abstract

Diabetes Ther (2018) 9:1269–1277 https://doi.org/10.1007/s13300-018-0436-y ORIGINAL RESEARCH Artiﬁcial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis . . . . Xia Dai Zu-chun Luo Lu Zhai Wen-piao Zhao Feng Huang Received: April 13, 2018 / Published online: May 9, 2018 The Author(s) 2018 Methods: Electronic databases were carefully ABSTRACT searched for English publications comparing artiﬁcial pancreas with its control group. Over- Introduction: Insulin injection is the main all daytime and nighttime glucose parameters treatment in patients with type 1 diabetes mel- were considered as the endpoints. Data were litus (T1DM). Even though continuous glucose evaluated by means of weighted mean differ- monitoring has signiﬁcantly improved the ences (WMDs) and 95% conﬁdence intervals conditions of these patients, limitations still (CIs) generated by RevMan 5.3 software. exist. To further enhance glucose control in Results: A total number of 354 patients were patients with T1DM, an artiﬁcial pancreas has included. Artiﬁcial pancreas signiﬁcantly main- been developed. We aimed to systematically tained a better mean concentration of glucose compare artiﬁcial pancreas with its control (WMD - 1.03, 95% CI - 1.32 to - 0.75; P = group during a 24-h basis in

Journal

Diabetes Therapy – Springer Journals

Published: May 9, 2018

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Artificial Pancreas as an Effective and Safe Alternative in Patients with Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis

References (40)

Abstract

Journal

Recommended Articles

There are no references for this article.

Our policy towards the use of cookies